Eliogreg
@eliogreg.bsky.social
MD, Medical Oncologist @ospNiguarda #LCSM #ThoracicOncology
Always find a way to have fun!
Always find a way to have fun!
TRACERx/PEACE: 501 samples from 24 #NSCLC pts (diagnosis→autopsy) reveal the metastatic cascade. Each met harbors a median of 7 subclones; 60% of mets seeded by OTHER mets (not primary);
CIN drives extrathoracic spread. Single met biopsies massively underestimate disease complexity
CIN drives extrathoracic spread. Single met biopsies massively underestimate disease complexity
May 1, 2026 at 6:47 PM
TRACERx/PEACE: 501 samples from 24 #NSCLC pts (diagnosis→autopsy) reveal the metastatic cascade. Each met harbors a median of 7 subclones; 60% of mets seeded by OTHER mets (not primary);
CIN drives extrathoracic spread. Single met biopsies massively underestimate disease complexity
CIN drives extrathoracic spread. Single met biopsies massively underestimate disease complexity
Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab url: aacrjournals.org/cancerdiscov...
Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab
AbstractThe bispecific antibody tarlatamab recruits T cells to cancers expressing the neuroendocrine epitope delta-like ligand 3 (DLL3). Tarlatamab is effective in small cell lung cancer (SCLC), but c...
aacrjournals.org
April 7, 2026 at 7:31 AM
Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab url: aacrjournals.org/cancerdiscov...
💫
Best of #ELCC26
#gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum:
→ Median OS: not reached vs 10 months
12mOS: 63vs30% (HR 0.46)
→ ORR: 20% vs 4.8%
→ Manageable safety profile
Best of #ELCC26
#gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum:
→ Median OS: not reached vs 10 months
12mOS: 63vs30% (HR 0.46)
→ ORR: 20% vs 4.8%
→ Manageable safety profile
March 27, 2026 at 8:56 PM
💫
Best of #ELCC26
#gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum:
→ Median OS: not reached vs 10 months
12mOS: 63vs30% (HR 0.46)
→ ORR: 20% vs 4.8%
→ Manageable safety profile
Best of #ELCC26
#gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum:
→ Median OS: not reached vs 10 months
12mOS: 63vs30% (HR 0.46)
→ ORR: 20% vs 4.8%
→ Manageable safety profile
🕐 more about #time-of-day and ICI
📋 IPD meta-analysis across 8 Roche/atezolizumab RCTs (n=3,060 #lung cancer pts). First 2 ICI cycles administered before vs. after 12:00 pm
🎯 OS HR late vs early: 1.039 (95% CI 0.925–1.168)
→ Upper limit < 1.18: non-inferiority demonstrated ✅
#ELCC2026
📋 IPD meta-analysis across 8 Roche/atezolizumab RCTs (n=3,060 #lung cancer pts). First 2 ICI cycles administered before vs. after 12:00 pm
🎯 OS HR late vs early: 1.039 (95% CI 0.925–1.168)
→ Upper limit < 1.18: non-inferiority demonstrated ✅
#ELCC2026
March 27, 2026 at 2:52 PM
🕐 more about #time-of-day and ICI
📋 IPD meta-analysis across 8 Roche/atezolizumab RCTs (n=3,060 #lung cancer pts). First 2 ICI cycles administered before vs. after 12:00 pm
🎯 OS HR late vs early: 1.039 (95% CI 0.925–1.168)
→ Upper limit < 1.18: non-inferiority demonstrated ✅
#ELCC2026
📋 IPD meta-analysis across 8 Roche/atezolizumab RCTs (n=3,060 #lung cancer pts). First 2 ICI cycles administered before vs. after 12:00 pm
🎯 OS HR late vs early: 1.039 (95% CI 0.925–1.168)
→ Upper limit < 1.18: non-inferiority demonstrated ✅
#ELCC2026
#AI on routine CT scans quantifies thymic health → predicts ICI outcomes in 3,476 patients across NSCLC, melanoma, renal & breast cancer — independent of PD-L1 and TMB.
Healthy thymus → ↑ TCR diversity → ↑ ICI efficacy. 🫁
#Immunotherapy #LungCancer #LCSM
Healthy thymus → ↑ TCR diversity → ↑ ICI efficacy. 🫁
#Immunotherapy #LungCancer #LCSM
Thymic health and immunotherapy outcomes in patients with cancer - Nature
A deep-learning approach applied to routine CT scans is used to quantify the health of the thymus in a cohort of patients with cancer, and shows that thymic function is associated with immunotherapy&n...
www.nature.com
March 22, 2026 at 7:47 PM
#AI on routine CT scans quantifies thymic health → predicts ICI outcomes in 3,476 patients across NSCLC, melanoma, renal & breast cancer — independent of PD-L1 and TMB.
Healthy thymus → ↑ TCR diversity → ↑ ICI efficacy. 🫁
#Immunotherapy #LungCancer #LCSM
Healthy thymus → ↑ TCR diversity → ↑ ICI efficacy. 🫁
#Immunotherapy #LungCancer #LCSM
MTAP loss has highest rates in ALK+ (up to 45%), followed by RET+ (up to 36%) and EGFR+ (up to 24%) NSCLC
IHC and NGS may be complementary for detection. #PRMT5i shows activity
PRMT5i + targeted therapy may outperform monotherapy in models
www.annalsofoncology.org/article/S092...
IHC and NGS may be complementary for detection. #PRMT5i shows activity
PRMT5i + targeted therapy may outperform monotherapy in models
www.annalsofoncology.org/article/S092...
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
Homozygous loss of MTAP (methylthioadenosine phosphorylase) occurs in approximately
15% of cancers and leads to partial PRMT5 inhibition, creating a selective vulnerability
to PRMT5 inhibitors. The fr...
www.annalsofoncology.org
March 16, 2026 at 9:48 PM
MTAP loss has highest rates in ALK+ (up to 45%), followed by RET+ (up to 36%) and EGFR+ (up to 24%) NSCLC
IHC and NGS may be complementary for detection. #PRMT5i shows activity
PRMT5i + targeted therapy may outperform monotherapy in models
www.annalsofoncology.org/article/S092...
IHC and NGS may be complementary for detection. #PRMT5i shows activity
PRMT5i + targeted therapy may outperform monotherapy in models
www.annalsofoncology.org/article/S092...
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial: Cancer Cell www.cell.com/cancer-cell/...
In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%)
In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%)
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
Wang et al. conducted an open-label, multicenter phase 1a/b study to evaluate the
safety, pharmacokinetics, and efficacy of HS-20093 in patients with advanced solid
tumors. HS-20093 demonstrated a man...
www.cell.com
March 14, 2026 at 10:09 PM
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial: Cancer Cell www.cell.com/cancer-cell/...
In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%)
In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%)
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors - ESMO Open www.esmoopen.com/article/S205...
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors
Combining radiotherapy (RT) with targeted agents may lead to improved treatment outcomes
across various tumor types. However, there is a risk of increased toxicity. Unfortunately,
high-quality toxicit...
www.esmoopen.com
March 2, 2026 at 8:07 PM
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors - ESMO Open www.esmoopen.com/article/S205...
Heads or the Tail? | New England Journal of Medicine www.nejm.org/doi/full/10....
Heads or the Tail? | NEJM
Survival in patients with cancer, affected by myriad factors, is notoriously difficult to predict. But while oncologists find it hard to communicate the uncertainty, patients are the ones who must ...
www.nejm.org
February 16, 2026 at 8:50 PM
Heads or the Tail? | New England Journal of Medicine www.nejm.org/doi/full/10....
Case series detailing immune checkpoint inhibitor related encephalitis (lung cancer, SCC, melanoma, lymphomas…). Most recovered with therapy
academic.oup.com/oncolo/artic...
In my experience, io-related encephalitis in mesothelioma are more dangerous
academic.oup.com/oncolo/artic...
In my experience, io-related encephalitis in mesothelioma are more dangerous
Immune-related encephalitis after immune checkpoint inhibitor therapy
Immune checkpoint inhibitors have revolutionized cancer treatment but can trigger immune-related encephalitis. This article reports one of the largest case
academic.oup.com
February 16, 2026 at 8:05 PM
Case series detailing immune checkpoint inhibitor related encephalitis (lung cancer, SCC, melanoma, lymphomas…). Most recovered with therapy
academic.oup.com/oncolo/artic...
In my experience, io-related encephalitis in mesothelioma are more dangerous
academic.oup.com/oncolo/artic...
In my experience, io-related encephalitis in mesothelioma are more dangerous
15% of LUAD lacked TTF-1 expression
-> lower PD-L1 & more frequent KRAS and high-risk mutations, such as STK11, KEAP1, & SMARCA4
-> TTF-1 negativity stratified outcomes even among pts with high-risk mutations
-> lower PD-L1 & more frequent KRAS and high-risk mutations, such as STK11, KEAP1, & SMARCA4
-> TTF-1 negativity stratified outcomes even among pts with high-risk mutations
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
Thyroid transcription factor-1 (TTF-1) expression, routinely assessed through immunohistochemistry
(IHC) in the diagnostic evaluation of lung adenocarcinomas (LUAD), is negative (TTF-1Neg)
in ∼15-20% ...
www.jto.org
February 13, 2026 at 6:21 AM
15% of LUAD lacked TTF-1 expression
-> lower PD-L1 & more frequent KRAS and high-risk mutations, such as STK11, KEAP1, & SMARCA4
-> TTF-1 negativity stratified outcomes even among pts with high-risk mutations
-> lower PD-L1 & more frequent KRAS and high-risk mutations, such as STK11, KEAP1, & SMARCA4
-> TTF-1 negativity stratified outcomes even among pts with high-risk mutations
Selective RET inhibitors:
Non-KIF5B → better PFS (17.0 vs 5.5 months)
Non-KIF5B → better PFS (17.0 vs 5.5 months)
RET Fusion–Positive lung Adenocarcinoma: Partner-Specific clinicopathological Characteristics, co-mutation Profiles, and Implications for targeted and Immunotherapy
Rearranged during transfection (RET) gene fusions are rare but actionable oncogenic
drivers in non-small cell lung cancer (NSCLC), occurring in approximately 1.0%–2%
of cases and predominantly in lung...
www.lungcancerjournal.info
February 13, 2026 at 6:15 AM
Selective RET inhibitors:
Non-KIF5B → better PFS (17.0 vs 5.5 months)
Non-KIF5B → better PFS (17.0 vs 5.5 months)
Too good to be true?
I would encourage people to check out the version control of this study on clinicaltrials.gov/study/NCT055....
The definition of early vs late, sample size, and inclusion criteria changed throughout the study period. Once it was even changed to be an observational study and then back to RCT??!
The definition of early vs late, sample size, and inclusion criteria changed throughout the study period. Once it was even changed to be an observational study and then back to RCT??!
February 7, 2026 at 9:06 PM
Too good to be true?
Interesting hypothesis about anti-TIGIT failure
“Selecting an unmutated IgG1 targeting TIGIT, LAG-3, TIM-3, or PD-1 may deplete effector T cells through CDC, ADCC, and/or ADCP, thereby counteracting anticancer efficacy”
#lcsm #tigit
“Selecting an unmutated IgG1 targeting TIGIT, LAG-3, TIM-3, or PD-1 may deplete effector T cells through CDC, ADCC, and/or ADCP, thereby counteracting anticancer efficacy”
#lcsm #tigit
Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies
ascopubs.org
February 7, 2026 at 8:18 AM
In long-term responders to 2y first-line ICB, PET/CT-guided Tx discontinuation was associated with improved OS vs continued therapy, HR 0.35
Re-biopsy identified frequent second primary lung cancers and distinct resistance biology ➡️ local management
#lungcancer #NSCLC #immunotherapy #ICI #PETCT
Re-biopsy identified frequent second primary lung cancers and distinct resistance biology ➡️ local management
#lungcancer #NSCLC #immunotherapy #ICI #PETCT
February 3, 2026 at 5:50 AM
In long-term responders to 2y first-line ICB, PET/CT-guided Tx discontinuation was associated with improved OS vs continued therapy, HR 0.35
Re-biopsy identified frequent second primary lung cancers and distinct resistance biology ➡️ local management
#lungcancer #NSCLC #immunotherapy #ICI #PETCT
Re-biopsy identified frequent second primary lung cancers and distinct resistance biology ➡️ local management
#lungcancer #NSCLC #immunotherapy #ICI #PETCT
This is huge.
Time of the day has an enormous impact on #immunotherapy outcome
Early immunochemo (<15:00) vs late:
📈 mPFS: 11.3 vs 5.7 mo (HR 0.40)
⏳ mOS: 28.0 vs 16.8 mo (HR 0.42)
🧬 ↑ CD8⁺ activation | similar safety
www.nature.com/articles/s41...
#lcsm #nsclc
Time of the day has an enormous impact on #immunotherapy outcome
Early immunochemo (<15:00) vs late:
📈 mPFS: 11.3 vs 5.7 mo (HR 0.40)
⏳ mOS: 28.0 vs 16.8 mo (HR 0.42)
🧬 ↑ CD8⁺ activation | similar safety
www.nature.com/articles/s41...
#lcsm #nsclc
February 2, 2026 at 7:44 PM
This is huge.
Time of the day has an enormous impact on #immunotherapy outcome
Early immunochemo (<15:00) vs late:
📈 mPFS: 11.3 vs 5.7 mo (HR 0.40)
⏳ mOS: 28.0 vs 16.8 mo (HR 0.42)
🧬 ↑ CD8⁺ activation | similar safety
www.nature.com/articles/s41...
#lcsm #nsclc
Time of the day has an enormous impact on #immunotherapy outcome
Early immunochemo (<15:00) vs late:
📈 mPFS: 11.3 vs 5.7 mo (HR 0.40)
⏳ mOS: 28.0 vs 16.8 mo (HR 0.42)
🧬 ↑ CD8⁺ activation | similar safety
www.nature.com/articles/s41...
#lcsm #nsclc
January 30, 2026 at 8:55 PM
#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
January 28, 2026 at 5:38 AM
#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
January 27, 2026 at 1:41 PM
Reposted by Eliogreg
#ARTICUNO study
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth fact…
www.sciencedirect.com
November 20, 2024 at 6:38 AM
#ARTICUNO study
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
Reposted by Eliogreg
BOYCOTT USA NOW!!!
It's time for all countries to stop doing business with this fascist country!!
Enough with the blackmailing and intimidations!!!
It's time for all countries to stop doing business with this fascist country!!
Enough with the blackmailing and intimidations!!!
January 16, 2026 at 5:03 PM
BOYCOTT USA NOW!!!
It's time for all countries to stop doing business with this fascist country!!
Enough with the blackmailing and intimidations!!!
It's time for all countries to stop doing business with this fascist country!!
Enough with the blackmailing and intimidations!!!
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA chuffed.org/project/1406...
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZAMentre il genocidio in corso a Gaza peggiora di giorno in giorno e le istituzioni restano in silenzio, persone da tutto il mondo si stanno mobilitando per co...
chuffed.org
August 14, 2025 at 12:20 PM
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA chuffed.org/project/1406...
A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.
#ELCC2025
More effort is needed to manage toxicity.
#ELCC2025
March 26, 2025 at 7:18 PM
A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.
#ELCC2025
More effort is needed to manage toxicity.
#ELCC2025
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) - Journal of Thoracic Oncology www.jto.org/article/S155...
March 10, 2025 at 3:43 PM
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) - Journal of Thoracic Oncology www.jto.org/article/S155...